Cargando…
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
Up to 40% of patients with advanced Hodgkin lymphoma (HL) become refractory or relapsed after current standard chemotherapy, among which primary refractory HL confers a particularly poor outcome. With intensive salvage chemotherapy and autologous stem cell transplantation, the long-term remission ra...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi Publishing Corporation
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808109/ https://www.ncbi.nlm.nih.gov/pubmed/24198983 http://dx.doi.org/10.1155/2013/351292 |